findmyKOL
Clinical trialNCT07095361RecruitingPhase 4Interventional

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

SponsorUniversity of North Carolina, Chapel HillEnrollment270Complicated Pleural Effusion/ EmpyemaEmpyemaEmpyema, PleuralPleural EffusionPleural Effusion Associated With Pulmonary InfectionPleural Infection Bacterial+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection. The investigators are trying to learn: * Does using the medicine once a day work just as well as using it twice a day? * Are there any differences in outcomes between patients who get the medicine once a day versus twice a day? * Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given? Participants will: * Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung. * Be asked to give permission to join the study. * Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jason Akulian, MD, MPH

    University of North Carollina at Chapel Hill

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Yale New Haven Hospital

    New Haven, Connecticut, United States

    Recruiting
  • Northwestern University

    Chicago, Illinois, United States

    Recruiting
  • Rush University Medical Center

    Chicago, Illinois, United States

    Recruiting
  • Henry Ford Hospital

    Detroit, Michigan, United States

    Recruiting
  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, United States

    Recruiting
  • Unc Chapel Hill

    Chapel Hill, North Carolina, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DNA degradation once dailyDNA degradation twice dailyFibrinolytic once dailyFibrinolytic twice daily
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Sept 2025
Primary completion
30 Sept 2028
Completion
30 Sept 2028
Last update posted
19 May 2026
Registered enrollment
270
Registry id
NCT07095361

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.